Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 718 participants.

Also called NCT01503021

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 718 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01503021
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01503021. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-04-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
Condition
End Stage Renal Disease
Intervention (Drug)
SFP
Intervention (Other)
Placebo
Lead sponsor
Rockwell Medical Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01503021
Content hash
5171c7daf983d48215efe25fd08dece26610a6f1f8899ff7ff414b15dd67be1a